Lanjuan Li

This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Zhejiang University, Shaoxing Tongchuang Biotechnology Co., Ltd.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lanjuan Li. Retrieved from https://idiyas.com/inventor/lanjuan-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 (Patent Applications = 4)

% Patents Active = 66.7

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 8(Granted Patents)

Location History:

Hangzhou, CN (2014)
Zhejiang, CN (2019)

Company Filing History:

Shaoxing Tongchuang Biotechnology Co., Ltd.

patent

Years Active: 2014-2025

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12446607 - Probiotic microcapsule and preparation method thereof (2025-10-21),

2. 10328122 - Method of treating fulminant hepatic failure using DLL4 cytokine (2019-06-25),

3. 8735143 - Hepatic lobule-like bioreactor (2014-05-27),

Title: Lanjuan Li - Innovator in Biotechnology

Introduction: Lanjuan Li is a prominent inventor based in Hangzhou, China. He is associated with Hangzhou Chichuang Biotechnology Co., Ltd. Despite having no granted patents, his contributions to the field of biotechnology are noteworthy. His work focuses on innovative methods for drug synthesis and immune cell analysis.

Latest Patent Applications: Lanjuan Li has been involved in several significant patent applications. One of his latest applications is titled "Synthesis Method of Targeted Drug nCoVshRNA 2ACE2." This method aims to create a targeted drug for the COVID-19 virus by designing a consensus RNAi sequence and synthesizing complementary siRNAs into a small hairpin-shaped shRNA. The process includes ligating ACE2 to the shRNA to facilitate targeted delivery to infected cells, thereby minimizing side effects. Another application is "Method for Establishing a Characteristic Atlas of Whole Immune Cells in Lungs of Mice with Acute Lung Injury." This invention provides a method for extracting and analyzing whole immune cells in the lungs, ensuring high yield and viability while allowing for comprehensive characterization of immune cell functions.

Conclusion: Lanjuan Li's innovative approaches in biotechnology demonstrate his commitment to advancing medical science. His latest patent applications reflect his dedication to addressing critical health challenges, particularly in the context of COVID-19 and immune response analysis.

Profile summary based on public USPTO records.